An observational study in Atrial Fibrillation (AF), Ischemic Stroke and Hemorrhagic Stroke, sponsored by Special Hospital for Cerebrovascular Diseases "Sveti Sava". Not yet recruiting at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Special Hospital for Cerebrovascular Diseases "Sveti Sava" · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Atrial Fibrillation with a site in Serbia — 5 open to participants now, 7 under way, 2 of them phase 3. Atrial Fibrillation · Serbia.
Among the 18 studies in Atrial Fibrillation with a site in Serbia, this one is the only one that started in 2026, is one of 3 observational ones, and was the 18th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.
Browse Atrial Fibrillation studies →5 of the 18 studies in Atrial Fibrillation with a site in Serbia are open now. Recruiting first, the newest first:
Institute of Cardiovascular Diseases, Vojvodina · Sites in Serbia
Ages 18+
Acesion Pharma · Sites in Serbia, Bulgaria, Denmark and 5 more countries
Ages 18+
Heart Care Foundation · Sites in Serbia, Bulgaria, Denmark and 3 more countries
Ages 65+
Anthos Therapeutics, Inc. · Sites in Serbia, United States, Argentina and 32 more countries
Ages 65+
A study can be open while its sites in Serbia have not opened yet or have stopped. Only those recruiting at a site in Serbia →
Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 300 across 1,404 observational studies indexed under Atrial Fibrillation.
Median enrollment 607 across the 15 interventional studies, 5,385 across the 3 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Special Hospital for Cerebrovascular Diseases "Sveti Sava" as lead sponsor.
Special Hospital for Cerebrovascular Diseases "Sveti Sava" has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies in Atrial Fibrillation with a site in Serbia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07267949Acesion PharmaClinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Atrial Fibrillation with a site in Serbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.
Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.
Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.
Pre-specified score (locked before enrollment): eGFR \<60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides \<=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE \<=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.
Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.
Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.
Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.
Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay.
Diagnostic Test: MASA score
Calculation of the MASA score (range 0-8) from routinely collected data: eGFR \<60 mL/min/1.73 m2 = 1 point; triglycerides \<=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter \>=46 mm = 1 point; TAPSE \<=17 mm = 2 points. A score \>=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score.
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
Sensitivity and specificity (with 95% confidence intervals) of a MASA score \>=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader.
Time frame: From ICU admission to ICU discharge (up to 30 days)
Positive and Negative Predictive Values of MASA Score >=5
Positive and negative predictive values (with 95% confidence intervals) of a MASA score \>=5 for atrial fibrillation detected by continuous ECG monitoring.
Time frame: From ICU admission to ICU discharge (up to 30 days)
Discriminative Performance of the MASA Score
Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test.
Time frame: From ICU admission to ICU discharge (up to 30 days)
Clinical Net Benefit of MASA-Guided Monitoring
Net benefit of selecting patients for extended ECG monitoring by MASA score \>=5, assessed by decision curve analysis.
Time frame: From ICU admission to ICU discharge (up to 30 days)
Number of Patients Monitored per Detected Atrial Fibrillation
Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score \>=5.
Time frame: From ICU admission to ICU discharge (up to 30 days)
Plan to share: Yes — De-identified individual participant data underlying the published results, together with the analysis code, will be made available.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: After publication of the primary results, for at least 5 years.
Access criteria: Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 24 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.